Login
Israel-Hamas Conflict
Memorial Day
Cannes Film Festival
Baseball
Social Media
World Cup
Premier League
Motorsports
Champions League
Sanctions
Disney
Wrestling
US Politics
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Discontinuation Did Not Reduce CheckMate 9LA Regimen’s Efficacy in NSCLC

Summary by targetedonc.com
David P. Carbone, MD, PhD, discusses the outcomes of the phase 3 CheckMate 9LA trial in non–small cell lung cancer based on treatment discontinuation.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
targetedonc.comtargetedonc.com

Discontinuation Did Not Reduce CheckMate 9LA Regimen’s Efficacy in NSCLC

David P. Carbone, MD, PhD, discusses the outcomes of the phase 3 CheckMate 9LA trial in non–small cell lung cancer based on treatment discontinuation.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

targetedonc.com broke the news in on Thursday, May 22, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

United States

United States

News
For You
SearchBlindspotLocal